12 completed. 12 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 12 |
Follow Episodic Migraine: new trials by email Literature Review of Episodic Migraine trials Research Report on Episodic Migraine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C) Click Digital Therapeutic - Migraine, Episodic Migraine | Phase 3 | Completed | Click Therapeutics, Inc. | 110 | 2023-07-21 | 2024-12-18 |
| Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments. Atogepant 60 mg, Placebo - Episodic Migraine | Phase 3 | Completed | Allergan | 315 | 2021-03-05 | 2023-09-21 |
| A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine Atogepant 60 mg - Episodic Migraine, Chronic Migraine | Phase 3 | Completed | AbbVie | 596 | 2021-02-19 | 2025-12-18 |
| A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine Atogepant 60 mg - Chronic Migraine, Episodic Migraine | Phase 3 | Completed | AbbVie | 186 | 2020-06-18 | 2025-07-22 |
| A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine Galcanezumab, Placebo - Episodic Migraine | Phase 3 | Completed | Eli Lilly and Company | 520 | 2019-07-30 | 2023-03-28 |
| Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine Atogepant - Episodic Migraine | Phase 3 | Completed | Allergan | 685 | 2019-05-06 | 2022-05-12 |
| Occipital Blocks for Acute Migraine Lidocaine 4% Topical Application Cream [LMX 4], Lidocaine Hydrochloride 2 mg/mL Injectable Solution, Normal Saline - Chronic Migraine, Headache, Episodic Migraine | Phase 3 | Completed | Children's Hospital of Philadelphia | 63 | 2019-04-03 | 2025-04-17 |
| 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine Atogepant, Placebo - Episodic Migraine | Phase 3 | Completed | Allergan | 910 | 2018-12-14 | 2021-07-09 |
| Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine Standard of Care (SOC) Migraine Preventive Medication, Atogepant - Episodic Migraine | Phase 3 | Completed | Allergan | 744 | 2018-10-08 | 2021-06-15 |
| Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients Erenumab, Placebo - Episodic Migraine | Phase 3 | Completed | Novartis Pharmaceuticals | 900 | 2018-02-08 | 2021-10-11 |
| A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies AMG334 (70 mg) Pre-Filled Syringe (PFS), Placebo Pre-Filled Syringe (PFS) - Episodic Migraine | Phase 3 | Completed | Novartis Pharmaceuticals | 246 | 2017-03-20 | 2022-03-23 |
| DFN-11 Injection in Episodic Migraine With or Without Aura DFN-11, Placebo - Episodic Migraine | Phase 3 | Completed | Dr. Reddy's Laboratories Limited | 268 | 2015-09-21 | 2018-07-26 |
Migraine Disorders (5) · Headache (4) · Epilepsy (3) · Pain (1) · Recurrence (1)
Brain Diseases (5) · Central Nervous System Diseases (5) · Headache Disorders (5) · Headache Disorders, Primary (5) · Nervous System Diseases (5) · Neurologic Manifestations (4) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Pain (3) · Disease Attributes (1) · Pathologic Processes (1)
atogepant (6) · Lidocaine (1) · Saline Solution (1) · Sodium Chloride (1) · Standard of Care (1) · erenumab (1) · galcanezumab (1)
Allergan (4) · AbbVie (2) · Novartis Pharmaceuticals (2) · Children's Hospital of Philadelphia (1) · Click Therapeutics, Inc. (1) · Dr. Reddy's Laboratories Limited (1) · Eli Lilly and Company (1)
United States (8) · Czechia (3) · Denmark (3) · France (3) · Germany (3) · Italy (3) · Netherlands (3) · Spain (3) · United Kingdom (3) · Australia (2) · Canada (2) · Hungary (2) · India (2) · Poland (2) · Russia (2)
Joel Trugman, MD (3) · Christina L. Szperka, MD, MSCE (1) · Shaheen Lakhan (1)
PMID 33142014, PMID 33942560, PMID 38462625, PMID 39648629, PMID 35978286, PMID 38773375, PMID 39648617, PMID 39715475, PMID 39982105, PMID 30112725, PMID 30112726, PMID 30360965, PMID 33402419, PMID 33910942, PMID 34171973, PMID 34407343, PMID 34521260, PMID 34845002, PMID 35675076, PMID 35896988, PMID 36396451, PMID 37542222, PMID 37638400, PMID 38364831, PMID 38669638, PMID 40831083, PMID 41641373, PMID 41814051, PMID 42129417
2016 (1), 2019 (1), K23NS102521 (1)